Table 3 A selected summary of the current studies using deep learning for secondary analysis of clinical trial data or design of clinical trials in ophthalmology
Author name (year) | Study population | Sample size | Treatment | Condition | Imaging | Outcome of interest |
|---|---|---|---|---|---|---|
Quantify structural changes | ||||||
Schmidt-Erfurth et al.148 | HAWK and HARRIER | 1078 and 739 | Brolucizumab OR Aflibercept | nAMD | OCT | IRF, SRF, PED |
Fu et al.149 | FILLY | 197 | Pegcetacoplan | GA | OCT | GA area, RPE loss, hypertransmission, PR degeneration, and intact macular area |
Vogl et al.150 | FILLY | 312 | Pegcetacoplan | GA | OCT | LPR, PR thickness, HRF concentration |
Roberts et al.151 | DRCR Network | 570 | Aflibercept, Ranibizumab, OR Bevacizumab | DME | OCT | IRF, SRF |
Schmidt-Erfurth et al.152 | OAKS and DERBY | 897 | Pegcetacoplan | GA | OCT | RPE loss and PR degeneration |
Predicting functional restoration | ||||||
Mulyukov et al.153 | HAWK and HARRIER | 594 + 389 | Brolucizumab OR Aflibercept | nAMD | OCT | Disease activity score |
Chandra et al.154 | CATT | 1029 | Ranibizumab OR Bevacizumab | nAMD | OCT | BCVA |
Kikuchi et al.155 | AVENUE | 273 | Faricimab | nAMD | OCT | BCVA and CST |
Maunz et al.156 | HARBOR | 432 | Ranibizumab | nAMD | OCT | BCVA |
Predicting treatment frequency | ||||||
Bogunovic ́ et al.157 | HARBOR | 317 | Ranibizumab | nAMD | OCT | Low (≤5 injection), High (≥16) |
Chandra et al. 158 | CATT | 493 | Ranibizumab OR Bevacizumab | nAMD | OCT | Low (≤8), High (≥19) |
